A new research study has shown that pancreatic cancer cells can be coaxed to revert back toward normal cells by introducing a protein called E47.
E47 binds to specific DNA sequences and controls genes involved in growth and differentiation. The research provides hope for a new treatment approach for the more than 40,000 people who die from the disease each year in the United States.
“For the first time, we have shown that overexpression of a single gene can reduce the tumor-promoting potential of pancreatic adenocarcinoma cells and reprogram them toward their original cell type. Thus, pancreatic cancer cells retain a genetic memory which we hope to exploit,” said Pamela Itkin-Ansari, Ph.D., adjunct professor in the Development, Aging, and Regeneration Program at Sanford-Burnham and lead author of the study published today in the journal Pancreas.
E47 turns the clock back
The study, a collaborative effort between Sanford-Burnham, UC San Diego, where Itkin-Ansari holds a joint appointment, and Purdue University, generated human pancreatic ductal adenocarcinoma cell lines to make higher-than-normal levels of E47. The increased amount of E47 caused cells to stall in the G0/G1 growth phase, and differentiate back toward an acinar cell phenotype.
In-vivo studies showed that when the reprogrammed cancer cells were introduced into mice, their ability to form tumors was greatly diminished compared to untreated adenocarcinoma cells.
“Presently, pancreatic adenocarcinoma is treated with cytotoxic agents, yet the average survival for patients post-diagnosis is merely six months, and the improvements in therapies are measured in days,” said Andrew M. Lowy, M.D., professor of surgery at the UC San Diego Moores Cancer Center and co-chair of the National Cancer Institute’s Pancreatic Cancer Task Force. “The finding that we can differentiate these cancer cells back to a non-threatening phenotype is encouraging. Indeed, there is a precedent for cell differentiation therapy in that the approach has been used to treat acute promyelocytic leukemia (APL) and some neuroblastomas successfully.”
“Our next step is to test primary patient-derived tumor tissue to determine whether E47 can produce similar results, potentially providing a novel therapeutic approach to combating this highly lethal disease,” said Itkin-Ansari. “Additionally, we are screening for molecules—potential drugs—that can induce overexpression of E47.”
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Study IDs 'Standard' Chemo for BRCA, PALB2 Pancreatic Canceron January 25, 2020 at 8:23 am
SAN FRANCISCO -- Gemcitabine (Gemzar) plus cisplatin should be considered a standard for metastatic pancreatic cancer patients with germline BRCA or PALB2 mutations, experts here said. In a randomized ...
- BioLineRx Concludes Recruitment in Pancreatic Cancer Studyon January 23, 2020 at 5:16 pm
closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.
- Hopeful New Therapies For Pancreatic Cancer Expected to be a Big Boon for Biotechson January 22, 2020 at 4:50 am
PALM BEACH, Florida, Jan. 22, 2020 /PRNewswire/ -- Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for ...
- Naperville sixth-grader sells shoe, streetwear with designs he created to raise money for pancreatic cancer researchon January 22, 2020 at 4:49 am
When Wes Selby’s grandmother was diagnosed with stage 4 pancreatic cancer in 2019, the 12-year-old Naperville boy wanted to do something to bring her hope. Wes turned his passion for drawing into ...
- BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Canceron January 22, 2020 at 3:00 am
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today the completion ...
- Pancreatic Cancer Market Share Growing Rapidly with Recent Trends, Revenue and Forecast to 2025on January 21, 2020 at 7:29 am
New York, January 21, 2020: The Global Pancreatic Cancer Market is expected to exceed more than US$ 13 billion by 2024. Browse Full Report: ...
- Chi-Med stops pivotal pancreatic cancer trial upon early successon January 21, 2020 at 5:40 am
Hutchison China MediTech has stopped a phase 3 trial of surufatinib in pancreatic neuroendocrine tumors early for positive efficacy. An independent data monitoring committee found the trial had hit ...
- A link between metabolic energetics and pancreatic cancer mechanosensingon January 20, 2020 at 8:19 am
Extracellular-matrix remodelling contributes to tumour progression, results in intratumoural fibrosis and promotes metastatic behaviour. A new study by Papalazarou et al. now reveals that a pathway ...
- Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic canceron January 17, 2020 at 3:11 am
Here, we report the development of two novel mAbs against CFPAC-1 human pancreatic cancer cells. Using ELISA, flow cytometry, immunoprecipitation, mass spectrometry, Western blot and ...
- 'Pulling the plug' on calcium pumps to kill pancreatic cancer cellson January 16, 2020 at 1:58 pm
UK scientists have identified a new way to kill pancreatic cancer cells by 'pulling the plug' on the energy generator that fuels calcium pumps on their cell surface. The study, published in the ...
via Bing News